Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
Background: Distress, anxiety, and other psychological disorders may be more common in people with primary brain tumors (PBTs). PBTs can affect their symptoms and quality of life. PBTs can also affect their tolerance of cancer treatments. Researchers want to learn if virtual reality (VR) technology can help. VR uses computer technology to make fake experiences and environments that look real. It lets people escape from their lives and experience more positive thoughts and emotions. Objective: To learn if it is feasible to use a VR relaxation intervention in people with PBT. Eligibility: Adults 18 and older who have a brain tumor and have recently reported psychological distress during their participation in the Natural History Study (NHS), protocol #16C0151 Design: Participants will give saliva samples at 4 time points. They will fill out 4 questionnaires at 4 times points. These forms are not part of the NHS. The 4 time points are: before the VR intervention in clinic after the VR intervention in clinic 1 week later at home 1 month later at home Participants will get a VR headset. It looks like a thick pair of goggles that goes over the eyes. Participants will view computer-generated environments on this headset. Participants will have a phone interview 1 week after the VR viewing. It will last 10 to 15 minutes. This study will also use the forms and questionnaires that the participants fill out as part of the NHS. Participation lasts 4 to 6 weeks.
Description: To describe the feasibility of implementing a VR intervention in a PBT population, including eligibility, accrual, compliance, adverse events, study completion, and participant satisfaction with the intervention
Measure: Number of participants who complete the sessions and questionnaires Time: End of StudyDescription: To assess the effects of a VR intervention on self-reported acute and subacute distress (as measured by the NCCN Distress Thermometer [DT]) and anxiety (as measured by the State Anxiety Inventory [STAI-6]) in PBT patients
Measure: Measurement of Distress Time: End of StudyDescription: To assess the effects of a VR intervention on self-reported mood disturbance (as measured by PROMIS - Anxiety & PROMIS - Depression Short Forms) and symptom burden and interference (as measured by the MD Anderson Symptom Inventory Brain Tumor [MDASI-BT])
Measure: Measurement of mood disturbance Time: End of StudyDescription: To determine if the effects VR has on distress and anxiety are more pronounced in those with high distress (based on DT cut-off score of greater than or equal to 5) compared those with to low distress (based on DT scores of 0-4)
Measure: Measurement of distress and anxiety Time: End of StudyDescription: To determine if the effects VR has on distress and anxiety are more pronounced in those individuals not on systemic corticosteroids (CS) compared to those who are
Measure: Measurement and comparison of distress and anxiety on those on systemic corticosteroids Time: End of StudyAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports